16,272 Shares in AbbVie Inc. $ABBV Bought by Davidson Capital Management Inc.

Key Points

• Davidson Capital Management purchased 16,272 AbbVie shares worth approximately $4.26 million in the third quarter, while institutional investors collectively own 70.23% of the company.
• AbbVie exceeded quarterly expectations, reporting $3.65 in EPS and $16.99 billion in revenue, with year-over-year revenue growth of 10.2%. The company guided for third-quarter 2026 EPS of $3.84 to $3.88.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $277.18. AbbVie also declared a quarterly dividend of $1.73 per share, while an executive recently sold 32,710 shares.

Davidson Capital Management Inc. purchased a new stake in AbbVie Inc. (NYSE:ABBV - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 16,272 shares of the company's stock, valued at approximately $4,257,000.

Several other institutional investors have also recently bought and sold shares of the stock. AdvisorNet Financial Inc boosted its holdings in AbbVie by 9.3% in the third quarter. AdvisorNet Financial Inc now owns 7,211 shares of the company's stock valued at $2,044,000 after acquiring an additional 616 shares during the last quarter. Weaver Capital Management LLC increased its position in AbbVie by 11.7% in the third quarter. Weaver Capital Management LLC now owns 13,965 shares of the company's stock worth $3,653,000 after purchasing an additional 1,467 shares during the period. Ninety One UK Ltd acquired a new stake in AbbVie in the third quarter worth about $746,000. Charles Schwab Trust Co raised its holdings in AbbVie by 1.8% during the 3rd quarter. Charles Schwab Trust Co now owns 32,249 shares of the company's stock worth $8,436,000 after purchasing an additional 557 shares during the last quarter. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors grew its stake in shares of AbbVie by 4.0% during the third quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors now owns 21,084 shares of the company's stock worth $5,516,000 after purchasing an additional 803 shares during the period. Institutional investors own 70.23% of the company's stock.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the business's stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares of the company's stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.06% of the company's stock.

AbbVie Stock Down 0.1%

Shares of NYSE ABBV opened at $283.07 on Friday. The company's fifty day moving average is $261.95 and its 200-day moving average is $238.90. The stock has a market cap of $500.13 billion, a price-to-earnings ratio of 79.96, a P/E/G ratio of 1.29 and a beta of 0.24. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $291.40.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. During the same quarter in the previous year, the business earned $2.97 EPS. The firm's revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts anticipate that AbbVie Inc. will post 13.94 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie's payout ratio is presently 195.48%.

Analyst Ratings Changes

A number of equities research analysts recently commented on ABBV shares. Royal Bank Of Canada reiterated an "outperform" rating and issued a $280.00 price objective on shares of AbbVie in a report on Tuesday. Guggenheim restated a "buy" rating and set a $288.00 target price on shares of AbbVie in a report on Friday, October 9th. Weiss Ratings upgraded AbbVie from a "buy (b-)" rating to a "buy (b)" rating in a research report on Thursday, October 8th. Erste Group Bank upgraded AbbVie from a "hold" rating to a "buy" rating in a research report on Wednesday, August 5th. Finally, Wells Fargo & Company upped their price target on AbbVie from $295.00 to $300.00 and gave the company an "overweight" rating in a research note on Monday, August 17th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $277.18.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New Phase 3 data for a subcutaneous version of SKYRIZI showed meaningful clinical and endoscopic benefits in adults with moderately to severely active Crohn’s disease. The results could support regulatory review of a more convenient induction option and strengthen confidence that SKYRIZI can help offset the loss of Humira revenue. Abbvie's Crohn's Disease Drug Skyrizi Shows More Positive Results
• Positive Sentiment: Analyst sentiment remains constructive. Royal Bank of Canada reaffirmed an Outperform rating, while Erste Group raised its 2027 EPS estimate to $16.34 from $16.19 and maintained a Buy rating. These views reinforce the argument that AbbVie’s newer drugs are driving sustainable post-Humira growth. Royal Bank Of Canada Reaffirms Outperform Rating for AbbVie
• Positive Sentiment: Investors are also watching early clinical work on oral candidate ABBV-1042. The study remains at an early stage and is being conducted in healthy participants, but positive progress could add value to AbbVie’s long-term pipeline. AbbVie's ABBV-1042 Trial Update
• Neutral Sentiment: AbbVie’s third-quarter earnings report is scheduled for October 30. Investors will be looking for confirmation that SKYRIZI and RINVOQ growth is more than compensating for Humira’s decline; the company’s current guidance calls for third-quarter EPS of $3.84 to $3.88. AbbVie's Q3 2026 Earnings: What to Expect
• Neutral Sentiment: Heavy call-option activity and a broad healthcare-sector rally indicate increased investor interest, but options positioning is not a fundamental catalyst by itself. Lower Treasury yields may also be supporting defensive healthcare shares.
• Negative Sentiment: Some investors remain concerned that AbbVie’s valuation is demanding after its rally. Comparisons with Sanofi have highlighted Sanofi’s stronger outlook and valuation, potentially limiting further upside. Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women's health.

The company's products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.